Max, the Warner Bros. Discovery streaming service, launched a new black-and-white color palette that evokes the same ...

Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) today and set a price target of Yen6,000.00. The company’s shares closed yesterday ...

Max is trading its bright blue branding and logo for a black-and-white color palette that evokes HBO’s classic branding.

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

J.P. Morgan analyst Seiji Wakao maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on March 5 and set a price target of Yen4,600.00. The company’s shares closed ...

Our collaboration with Daiichi Sankyo is an exciting opportunity to unlock therapeutic access to new cell types, paving the way for precision treatments that can transform patient outcomes." ...

AstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, worth up to $6 billion. The deal covers DS-1062, Daiichi Sankyo’s proprietary ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. December 24 ...

Just a few years after debuting its original logo, the Max streaming service, surprised users with an updated new logo and ...